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.e role of OqxAB eﬄux pump in Klebsiella pneumoniae was investigated in correlation with ciproﬂoxacin exposure. K.
pneumoniae SE23 and K. pneumoniae SE191 were isolated from urinary tract infections and were analyzed in this study. Each
carried oqxAB resistance determinant and exhibited ciproﬂoxacin MIC of 0.06 and 0.5mg/L, respectively. Tested strains were
initially exposed to their ciproﬂoxacinMIC values for 24 hours. Later on, the ciproﬂoxacin exposition has been increased to a daily
1, 2, 4, and to a ﬁnal 8mg/L. Total cellular RNA was extracted at 30, 60, 90, and 120 minutes of initial exposure and after every 24
hours. Quantitative reverse-transcriptase PCR was performed from each RNA sample. Mutation in gyrA and parC genes was
analyzed in each strain and multilocus sequence typing (MLST) was performed. Ciproﬂoxacin exposure selected resistant strain
from K. pneumoniae SE191; by contrast, K. pneumoniae SE23 was not adjustable to the increasing ciproﬂoxacin concentrations.
During initial exposure, both oqxA and oqxB expression remained low (2−ΔCt � 1-2.03). However, increasing ciproﬂoxacin
promoted oqxB expression as it reached fold increase of 15.8–22.8, while oqxA expression was maintained (2−ΔCt � 2-2.15). An
amino acid substitution Ser83Tyr in gyrA was detected in K. pneumoniae SE191, but no additional mutations occurred as
consequence to ciproﬂoxacin exposure. MLST identiﬁed K. pneumoniae SE191 as ST274, while K. pneumoniae SE23 belonged to
the novel ST2567. Ciproﬂoxacin concentration-dependent upregulation of oqxAB eﬄux pump in K. pneumoniae is clonally
related and contributes to selection for higher level of ﬂuoroquinolone resistance.
1. Introduction
Klebsiella pneumoniae is one of the most widespread nos-
ocomial pathogen and responsible for various infectious
diseases, including urinary tract, bloodstream, and re-
spiratory tract infections. It is capable of developing re-
sistance to cephalosporins, carbapenems, ﬂuoroquinolones,
aminoglycosides, and recently to polymyxins [1–3]. Fluo-
roquinolone resistance in K. pneumoniae is explained by
mutations in gyrase and topoisomerase IV enzymes; how-
ever, reduced susceptibility to ﬂuoroquinolones and low-
level resistance is maintained by plasmid-mediated quino-
lone resistance (PMQR) determinants, namely, Qnr de-
terminants, QepA and OqxAB eﬄux pumps, and
aminoglycoside-acetyltransferase Ib-cr enzyme [4].
OqxAB eﬄux pump belongs to the resistance nodulation
division family and it is constructed by two main domains,
namely, OqxA, a periplasmic part, and OqxB, a trans-
membrane protein. Its eﬄux pump activity is described in
a TolC-independent way; however, presence of an outer
membrane protein enhances its eﬀect [5]. OqxAB has been
commonly found chromosomally in K. pneumoniae and
usually plasmid located in other Enterobacteriaceae species.
.is resistance determinant is responsible to develop reduced
susceptibility and even resistance to olaquindox and other
ﬂuoroquinolone agents such as ciproﬂoxacin, norﬂoxacin, and
ﬂumequine [5, 6]. High prevalence of OqxAB has been de-
scribed in K. pneumoniae on both chromosome and plasmids
representing a potential reservoir of this resistance determinant
[7–10]. In K. pneumoniae, upregulation of oqxAB eﬄux pump
is rarA mediated; by contrast, oqxR is capable of down-
regulating it [11–13]. It has been recently reported that AcrAB
associated with overexpression of OqxAB is required for high
virulence potential in K. pneumoniae [14].
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Internationally successful high-risk clones of K. pneu-
moniae have disseminated in Hungary. .ese clones were
ﬂuoroquinolone resistant and harboured extended-
spectrum beta-lactamases (blaCTX-M-15) or carbapenemases
(blaVIM-4, blaKPC); however, they retained ﬁtness and these
combined features contributed to the widespread dissemi-
nation of ST11, ST15, ST147, and ST258 in hospital settings
and made them responsible for the majority of healthcare-
associated infections [15–17]. Recently, ST274 has emerged
in adult and newborn hospital wards and has been reported
in several nosocomial infections [17]. .e aim of this study
was to analyze role of oqxAB eﬄux pump in selection of
ﬂuoroquinolone resistance in diﬀerent K. pneumoniae
clones.
2. Materials and Methods
2.1. Bacterial Strains. Two K. pneumoniae strains (K.
pneumoniae SE23 and K. pneumoniae SE191) have been
included in this study. Both have been previously found
positive to oqxAB resistance determinant by PCR and
nucleic acid sequencing and lacked all other PMQRs. An-
timicrobial susceptibility testing was performed by micro-
dilution method based on documents of the European
Committee on Antimicrobial Susceptibility Testing
(EUCAST), and both K. pneumoniae SE23 and K. pneu-
moniae SE191 were found susceptible to ciproﬂoxacin with
MIC 0.06 and 0.5mg/L, respectively, based on EUCAST
breakpoints issued in the year 2016. However, ciproﬂoxacin
resistance breakpoint of Enterobacteriaceae has been revised
by EUCAST in 2017, indicating 0.5mg/L value as non-
susceptible to ﬂuoroquinolones.
2.2. Exposure to Ciproﬂoxacin. Each tested strain has been
prepared in 0.5 McFarland density in Mueller-Hinton broth
and has been initially exposed to their ciproﬂoxacin MIC
values of 0.06 and 0.5mg/L for 24 hours at 37°C. RNA
extraction has been carried out at 30, 60, 90, and 120minutes
and at 24 hours of ciproﬂoxacin exposition. Later on, after
the initial incubation, each tested strain has been adjusted to
0.5 McFarland density and has been exposed to an increased
ciproﬂoxacin concentration. In the case of K. pneumoniae
SE23, the peak ciproﬂoxacin exposition was 0.5mg/L. On
the other hand, K. pneumoniae SE191 was capable of
adapting to a daily increasing 1, 2, 4, and 8mg/L cipro-
ﬂoxacin exposition, where each incubation at 37°C lasted for
24 hours. After each daily exposure, RNA extraction has
been performed from each sample to analyze expression of
oqxAB eﬄux pump.
2.3. Quantitative Reverse-Transcriptase PCR Analysis for
Expression of oqxAB. Total cellular RNA was extracted from
both tested strains at given time point of incubation by
RNeasy Mini Kit (Qiagen GmbH, Hilden, Germany)
according to the manufacturer’s instructions. .e quanti-
tative RT-PCR was carried out in a Step One Real-Time PCR
System (Applied Biosystems, .ermo Fisher Scientiﬁc) with
following thermal proﬁle: 60°C for 30 sec; 50°C for 5min and
95°C for 10min; 40 cycles of 95°C for 15 sec and 60°C for
1min; and 60°C for 30 sec.
To test separate expression of the oqxA and oqxB gene,
the internal fragments were used to design set of primers and
6-FAM- or VIC-labelled probes. Chromosomal rpoB was
chosen as housekeeping gene. All oligonucleotide primers
and probes for quantitative RT-PCR were designed by
Primer Express 3.0 software and are listed in Table 1. Each
sample was tested in triplicate. .e Ct values of genes of
interest were normalized (ΔCt) to the Ct values of house-
keeping gene rpoB, and the relative expression of each gene
of interest was calculated as 2−ΔCt.
2.4. Analysis of Mutations in gyrA and parC Genes.
Mutations in gyrA and parC genes have been investigated by
PCR and nucleic acid sequencing. Set of primers was
designed by online tools of MWG Euroﬁns Operon and
synthetised by IDT Bioscience. PCR thermal proﬁle was as
follows: initial denaturation at 95°C for 3min, 30 cycles of
95°C for 1min, 52°C for 1min, 72°C for 1min, and an
additional extension at 72°C for 5min.
2.5. Multilocus Sequence Typing (MLST) of K. pneumoniae.
Each tested strain has been analyzed by multilocus sequence
typing based on sequences of seven housekeeping genes,
namely, gapA, infB, mdh, pgi, phoE, rpoB, and tonB. Oli-
gonucleotide primers and PCR thermal proﬁles were applied
after Diancourt et al. article [18] and as it is highlighted on
MLST database website http://bigsdb.pasteur.
fr/klebsiella/primers_used.html.
Amplicons of MLST, gyrA and parC PCR were analyzed
by electrophoresis in a 1.5% agarose gel (Sigma-Aldrich) at
120V for 20min in 1xTAE (40mMTris-HCl (pH 8.3), 2mM
acetate, and 1mM EDTA), and gel was stained with
0.05mg/L GelRed dye (Biotium) and visualised on a UV
transilluminator. PCR-positive amplicons were puriﬁed by
QIAquick PCR Puriﬁcation Kit (Qiagen GmbH, Hilden,
Germany), and nucleic acid sequencing was performed by
BIOMI Kft. Go¨do¨llő, Hungary.
2.6. Statistical Analysis. Expression level diﬀerences were
analyzed by t-test for 2 independent means.
3. Results
K. pneumoniae SE23 and K. pneumoniae SE191 strains were
positive to oqxAB by PCR and were both initially exposed to
ciproﬂoxacin concentration of their MIC values 0.06 and
0.5mg/L, respectively. However, selection of resistant strains
was successful only by K. pneumoniae SE191 and it was
found to be adjustable for further ciproﬂoxacin exposition.
Hence, multiple conditions K. pneumoniae SE23 was not
capable of adapting to increased ciproﬂoxacin concentra-
tions. .e highest ciproﬂoxacin value was 0.5mg/L, where
RNA could have been extracted from K. pneumoniae SE23,
but no further exposition was possible.
2 Canadian Journal of Infectious Diseases and Medical Microbiology
Quantitative RT-PCR was performed on RNA samples
taken at given time points of ciproﬂoxacin exposure to in-
vestigate expression level diﬀerences of oqxAB eﬄux pump.
Expression in SE191 to 0.5mg/L for 30 minutes was 1.82 and
no relevant expression change to 4 and 8mg/L as 2−ΔCt values
were 2.15 and 2.00. In the case of SE23 expression, 2−ΔCt
values were 1.07 and 1 at maximum 0.5mg/L (Figure 1).
In the case of OqxAB, expression level values calculated
as 2−ΔCT were 1.47 and 1.73 for SE191 while in SE23 values
were 1.78 and 1.59. .e change in expression of SE191 to 4
and 8mg/L concentrations was in time 15.8 and 22.8
(Figure 1). Expression analysis by t-test showed t val-
ue� 1.88 and p value� 0.04.
In the case of SE191, a Ser83Tyr mutation in gyrase A has
been detected. .is mutation presented the 0.5mg/L MIC
value. In SE23, amino acid substitutions have not been at
0.5mg/L exposition.
MLST has been conducted on both strains. K. pneu-
moniae SE191 was identiﬁed as ST274, while K. pneumoniae
SE23 presented the novel ST2567. .is novel sequence type
incorporated a new tonB variant 371, which had two mu-
tations at C48A and G61C compared to its closest match
allele 87. Other alleles of K. pneumoniae SE23 yielded gapA
4, infB 31,mdh 13, pgi 1, phoE 1, and rpoB 1..e nucleic acid
sequence of novel tonB allele 371 and the MLST proﬁle of
ST2567 have been submitted to K. pneumoniae database
(http://bigsdb.pasteur.fr/klebsiella/klebsiella.html).
4. Discussion
Our study demonstrated role of OqxAB eﬄux pump in K.
pneumoniae during exposure to increased ciproﬂoxacin
concentrations. K. pneumoniae SE23 and K. pneumoniae
SE191 belonging to diﬀerent sequence types ST2567 and
ST274, respectively, have been investigated. .ey showed
varying ability to adapt to ciproﬂoxacin exposition, though
both strains carried oqxAB eﬄux pump. .e two tested
strains exhibited diﬀerent ciproﬂoxacin MIC values 0.06 and
0.5mg/L, respectively, and both were susceptible based on
the EUCAST 2016 documents (valid at the time when this
experiment was started). .e initial exposure selected re-
sistant strains only in the ST274 clone and it was further
exposed to higher ciproﬂoxacin concentrations untill
8mg/L..is strain harboured already a Ser83Tyr amino acid
substitution in gyrase A subunit, but no other mutations
occurred as consequence to ciproﬂoxacin exposure. An
Table 1: Oligonucleotide primers and probes of this study.
Primer or probe Sequence Reference
gyrA fwd CAGCCCTTCAATGCTGATG Designed in the study
gyrA rev CGCTTTTACTCCTTTTCTGTTC Designed in the study
parC fwd CTCAATCAGCGTAATCGCC Designed in the study
parC rev AATCCTCAGCCGATCTCAC Designed in the study
Kpn.rpoBF1 fwd GTCGCGGCTGAACAAGCT Designed in the study
Kpn.rpoBR1 rev AACGGCCACTTCGTAGAAGATC Designed in the study
Kpn.rpoBP1-VIC probe CTACGGCAGGTAACC Designed in the study
oqxAF1 fwd GTCGACGGCTTACAAAAAGTGTT Designed in the study
oqxAR1 rev GCAACGGTTTTGGCGTTAA Designed in the study
oqxAP1-FAM probe ATGCCGGGTATGCC Designed in the study
oqxBF1 fwd CTGGATTTTCCGTCCGTTTAAC Designed in the study
oqxBR1 rev TTGCCTACCAGTCCCTGATAGC Designed in the study
oqxBP1-FAM probe CTGCGCAGCTCGAA Designed in the study
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oqxB K. pneumoniae SE191
Figure 1: Expression in SE23 and SE191.
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upregulation of oqxB has been detected with a fold change of
22.8 times increase in expression during the ciproﬂoxacin
exposure from 0.5 till 8mg/L. .is upregulation and se-
lection of resistant strains seem clonally dependent as K.
pneumoniae SE23, a strain of ST2567, could not increase the
expression level of oqxAB and failed to adapt to an in-
creasing ciproﬂoxacin concentration. .is upregulation of
eﬄux pump can contribute to the ﬁtness of ST274, as it has
been identiﬁed as one of the disseminated clones in newborn
and adult hospital wards in Hungary [17].
Results of our study are in accordance with recent cipro-
ﬂoxacin breakpoint modiﬁcation of EUCAST. Our study had
begun in 2016; therefore, antimicrobial susceptibility testing and
interpretation of results were based on EUCAST 2016 docu-
ments where 0.5mg/L ciproﬂoxacin value was in susceptible
range..e resistance breakpoint of Enterobacteriaceae has been
revised in 2017 and set 0.5mg/L in nonsusceptible range. K.
pneumoniae SE191 exhibiting 0.5mg/L ciproﬂoxacin MIC was
capable of developing further ﬂuoroquinolone resistance by
upregulation of oqxAB eﬄux pump due to ciproﬂoxacin ex-
posure. By contrast, K. pneumoniae SE23 exhibiting 0.06mg/L
ciproﬂoxacin MIC and lacking increased oqxAB expression
during exposure to ciproﬂoxacin was not able to adapt to
ﬂuoroquinolone exposition and could not develop resistance.
In our study, a novel K. pneumoniae sequence type has
been detected, namely, ST2567 that was distinguished by two
mutations in tonB allele from its closest sequence type 2387.
.e newK. pneumoniae STproﬁle has been deposited toMLST
database (http://bigsdb.pasteur.fr/klebsiella/klebsiella.html).
Earlier studies demonstrated OqxAB eﬄux pump in
extended-spectrum beta-lactamase-producing and
ﬂuoroquinolone-resistant K. pneumoniae high-risk clones
[19–21]. In Hungary, K. pneumoniae with oqxAB resistance
determinant was reported in bloodstream infections [22]. In
all these reported studies, tested strains were resistant to
ﬂuoroquinolones. In our study, we demonstrated the role of
oqxAB eﬄux pump in K. pneumoniae in selection of re-
sistance to ﬂuoroquinolones. Our two tested strains were
susceptible to ﬂuoroquinolones, but after exposure to
ciproﬂoxacin, the one with gyrAmutation could be selected to
higher levels of ﬂuoroquinolone resistance. Additional
chromosomal mutations of gyrA and parC genes in tested
strain did not occur, suggesting that the development of
resistance during exposure to 0.5–8mg/L ciproﬂoxacin was
mainly caused by the increased expression of the oqxAB eﬄux
pump gene. Strains were exposed to the maximum of 8mg/L
ciproﬂoxacin concentration, and in human tissues, cipro-
ﬂoxacin is unable to reach higher concentrations during a per
os dosing; thus, the concentrations used in our study can
represent a ﬂuoroquinolone exposure during per os therapy.
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